R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Director Global MSL Excellence

Biology & BiotechConfirmed live in the last 24 hours
Full-timeRemote in USA

About the Job

Requirements

  • An advanced degree is required: PharmD, PhD, MD, or equivalent in life sciences.
  • At least 10 years of progressive experience in biotech or pharmaceutical Medical Affairs, including at least 5 years in Field Medical or MSL Excellence leadership.
  • Demonstrated success developing global Field Medical strategies, competency frameworks, and learning programs.
  • A proven track record enhancing MSL effectiveness, insights processes, and scientific engagement quality.
  • Experience with global medical systems such as Veeva PromoMats, digital enablement, data analytics, and process optimization.
  • Strong knowledge of medical compliance standards and inspection readiness best practices.

Responsibilities

  • Lead the creation and execution of a cohesive global MSL excellence strategy aligned with medical and corporate objectives.
  • Establish global standards for scientific exchange, insights generation, field activity execution, and external engagement.
  • Partner with regional Field Medical leaders to ensure consistency while enabling region-specific adaptability.
  • Develop and maintain a global MSL competency model, certification programs, and role expectations.
  • Partner with Medical Content and Training to design field medical onboarding programs and continuous learning curricula, including scientific acumen, communication skills, engagement planning, and compliance requirements.
  • Partner with Medical Content and Training to plan and execute integrated launch trainings, new data, congress preparation, and medical platforms.
  • Partner with Medical Analytics and Insights/Medical Solutions teams to streamline insights capture, governance, and analytics, driving high-quality, actionable intelligence into medical strategy.
  • Define KPIs and dashboards measuring MSL performance, impact, and scientific engagement excellence to foster continuous improvement.
  • Conduct quality reviews of field interactions, insights, and medical planning outputs, and recommend improvements to enhance scientific value.
  • Oversee global processes supporting Field Medical, including scientific engagement planning, territory management, stakeholder mapping, and compliant documentation.
  • Collaborate on digital transformation initiatives, including Veeva PromoMats and CRM, Learning Management Systems, insights platforms, and congress planning systems, to optimize Field Medical workflows and data visibility.
  • Ensure operational readiness for global milestones, launches, and cross-functional initiatives.
  • Serve as a key advisor and strategic partner to Field Medical leadership across regions.
  • Establish governance structures for Field Medical excellence, including global councils, working groups, and capability forums.
  • Collaborate with Medical Communications, Clinical Development, and other partners to ensure scientific alignment and integrated medical planning.
  • Ensure Field Medical activities adhere to global and regional regulations, including FDA, EMA, GxP, ICH, PhRMA, and Sunshine Act requirements, company policies, and medical governance.
  • Support audit and inspection readiness activities for Field Medical operations.

Desired Qualifications

  • Oncology and/or precision medicine experience is strongly preferred.
  • Experience building or scaling Field Medical organizations during rapid growth or product launch phases.
  • Expertise in global engagement planning, medical impact metrics, and competency-based training models.
  • Familiarity with global healthcare systems and regional Medical Affairs nuances.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs